BR112013006683A2 - diagnóstico de câncer de mama - Google Patents

diagnóstico de câncer de mama

Info

Publication number
BR112013006683A2
BR112013006683A2 BR112013006683A BR112013006683A BR112013006683A2 BR 112013006683 A2 BR112013006683 A2 BR 112013006683A2 BR 112013006683 A BR112013006683 A BR 112013006683A BR 112013006683 A BR112013006683 A BR 112013006683A BR 112013006683 A2 BR112013006683 A2 BR 112013006683A2
Authority
BR
Brazil
Prior art keywords
cancer
patient
breast cancer
cancer diagnosis
determining
Prior art date
Application number
BR112013006683A
Other languages
English (en)
Inventor
Daniel Schramek
Georg Schett
Ian J Jacobs
Josef Penninger
Martin Schwendter
Usha Menon
Original Assignee
Imba Inst Für Molekulare Biotechnologie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imba Inst Für Molekulare Biotechnologie Gmbh filed Critical Imba Inst Für Molekulare Biotechnologie Gmbh
Publication of BR112013006683A2 publication Critical patent/BR112013006683A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

diagnóstico de câncer de mama. a presente invenção refere-se a métodos e meios para detectar câncer ou prever que um paciente desenvolverá câncer ou para determinar a taxa de progressão do câncer em um paciente tem câncer, que compreende determinar a atividade de rankl e/ou quantidade de opg em uma amostra do dito paciente.
BR112013006683A 2010-09-22 2011-09-22 diagnóstico de câncer de mama BR112013006683A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10178345A EP2434285A1 (en) 2010-09-22 2010-09-22 Breast cancer diagnostics
PCT/EP2011/066514 WO2012038505A1 (en) 2010-09-22 2011-09-22 Breast cancer diagnostics

Publications (1)

Publication Number Publication Date
BR112013006683A2 true BR112013006683A2 (pt) 2016-06-07

Family

ID=43302989

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013006683A BR112013006683A2 (pt) 2010-09-22 2011-09-22 diagnóstico de câncer de mama

Country Status (15)

Country Link
US (2) US20130316374A1 (pt)
EP (2) EP2434285A1 (pt)
JP (1) JP6006216B2 (pt)
KR (1) KR20130101062A (pt)
CN (1) CN103238067B (pt)
AU (1) AU2011306918B2 (pt)
BR (1) BR112013006683A2 (pt)
CA (1) CA2811558A1 (pt)
DK (1) DK2619582T3 (pt)
ES (1) ES2533762T3 (pt)
IL (1) IL225441A0 (pt)
MX (1) MX2013003077A (pt)
NZ (1) NZ608208A (pt)
RU (1) RU2013118332A (pt)
WO (1) WO2012038505A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然複合ホルモン補充製剤および療法
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150276748A1 (en) * 2012-10-25 2015-10-01 Cedars-Sinai Medical Center Methods of prognosticating and treating cancer
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP6554087B2 (ja) 2013-03-14 2019-07-31 オートレイシーズ・インコーポレイテッドＯＴｒａｃｅｓ Ｉｎｃ． 測定分析物を使用する、疾患診断を改善するための方法
WO2015097977A1 (ja) * 2013-12-24 2015-07-02 ソニー株式会社 検査サーバ、通信端末、検査システム、および検査方法
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3405896A4 (en) 2016-01-22 2019-09-25 Otraces Inc. SYSTEMS AND METHODS FOR ENHANCING DIAGNOSIS OF DISEASE
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
JP2022541689A (ja) * 2019-07-13 2022-09-26 オートレイシーズ，インク． 腫瘍微小環境活性蛋白質を用いる種々の疾患の診断の改善

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2144386T5 (es) 1996-12-23 2012-12-07 Immunex Corporation Ligando para el activador del receptor de NF-kappa b, el ligando es miembro de la superfamilia de TNF
CA2781623A1 (en) 1997-04-15 1998-10-22 Daiichi Sankyo Company, Limited Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
SI0975754T2 (sl) 1997-04-16 2016-04-29 Amgen Inc., Vezivni proteini in receptorji osteoprotegerina
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
WO1998054201A1 (en) 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US20040002067A1 (en) * 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
WO2005060627A2 (en) * 2003-12-10 2005-07-07 Auxeris Therapeutics, Inc. Methods of assessing the risk of non-traumatic bone fracture
US20080107597A1 (en) 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
EP2020445B1 (en) * 2006-05-12 2013-01-02 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
CN101514232B (zh) * 2009-03-25 2013-06-19 上海科新生物技术股份有限公司 一种RANKL-Fc融合蛋白及其制备方法和用途
CN101571545A (zh) * 2009-06-09 2009-11-04 广州益善生物技术有限公司 用于多项肿瘤骨转移标志物并行检测的液相芯片及其制备方法

Also Published As

Publication number Publication date
RU2013118332A (ru) 2014-10-27
EP2619582B1 (en) 2015-01-07
JP6006216B2 (ja) 2016-10-12
IL225441A0 (en) 2013-06-27
WO2012038505A1 (en) 2012-03-29
CN103238067A (zh) 2013-08-07
EP2434285A1 (en) 2012-03-28
ES2533762T3 (es) 2015-04-14
NZ608208A (en) 2014-07-25
MX2013003077A (es) 2013-07-29
US20130316374A1 (en) 2013-11-28
AU2011306918A1 (en) 2013-04-04
AU2011306918B2 (en) 2014-08-07
KR20130101062A (ko) 2013-09-12
US20170102388A1 (en) 2017-04-13
JP2013542419A (ja) 2013-11-21
DK2619582T3 (en) 2015-01-19
CA2811558A1 (en) 2012-03-29
CN103238067B (zh) 2014-12-17
EP2619582A1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
BR112013006683A2 (pt) diagnóstico de câncer de mama
IL254062B (en) Kits containing ptk7 antibody and their use in the treatment, detection, diagnosis or monitoring of cancer
BR112014020211A2 (pt) métodos para analisar uma série ordenada por tempo de medições de um polímero, para estimar a presença, ausência ou quantidade de um polímero alvo, e para determinar uma alteração em um polímero, programa de computador, e, dispositivos de análise e de diagnóstico
EA201590027A1 (ru) Способы детекции заболеваний или состояний
BR112013000745A2 (pt) "método para diagnosticar ou detectar câncer colorretal em um individuo, método de tratamento e método para monitorar a eficacia de tratamento de câncer colorretal em um indivíduo"
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
EP2596132A4 (en) METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
GB2519906A (en) Methods and systems for detecting biological components
EP2576837A4 (en) CIRCULATING NUCLEIC ACID BIOMARKERS ASSOCIATED WITH PROSTATE CANCER
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
MX361058B (es) Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
BR112015003046A2 (pt) sistema de neurofeedback, processador de sinal para determinação de uma característica do sinal do sinal do biofeedback medido, método para provisão de um usuário com o neurofeedback e programa de computador.
PH12014502436A1 (en) In vitro method for the diagnosis and surveillance of cancer
WO2011139721A8 (en) Cancer biomarkers and methods of use thereof
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
EP3004394A4 (en) ASSAYS, METHODS AND KITS FOR ANALYZING SENSITIVITY AND RESISTANCE TO ANTICANCER DRUGS, GIVING PROGNOSTIC CANCER PATIENT, AND PERSONALIZED THERAPEUTIC STRATEGIES
SG11201508544VA (en) Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
WO2012109632A3 (en) Crown-like structures as a biomarker for cancer risk and cancer prognosis
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
IN2014DN08398A (pt)
BR112015027249A2 (pt) método de diagnóstico de câncer
PT2473854T (pt) Sistemas e métodos para tratar, diagnosticar e prever a resposta à terapia do cancro de mama
IN2015DN01646A (pt)
EP2601530A4 (en) COMPOSITIONS AND METHODS OF DETECTING, DIAGNOSING AND TREATING CANCER

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]